Aflibercept in persistent neovascular AMD: Comparison of different treatment strategies in switching therapy

Eye (Basingstoke)

Volumn 30, Issue 8, 2016, Pages 1077-1083

  Ricci, F ^a   Parravano, M ^b   Regine, F ^a   Sciamanna, M ^b   Tedeschi, M ^b   Missiroli, F ^a   Varano, M ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE BIETTI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; FLUORESCEIN; INDOCYANINE GREEN; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EYE DISEASE; FEMALE; FOLLOW UP; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; LOADING DRUG DOSE; MALE; POLYPOIDAL CHOROIDAL VASCULOPATHY; RECOMMENDED DRUG DOSE; RETINA DETACHMENT; RETINA NEOVASCULARIZATION; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; SYSTEMIC DISEASE; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DRUG SUBSTITUTION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84982181964     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2016.95     Document Type: Article

References (26)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004; 291: 1900-1901.
2. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
3. Rosenfeld PG, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
4. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-372.
5. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E et al. Binding and neutralization of endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012; 15: 171-185.
6. Rakic J, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 3186-3193.
7. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119: 2537-2548.
8. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninetysix-week results of the VIEW studies. Ophthalmology 2014; 121: 193-201.
9. Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2013; 33: 1605-1612.
10. Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE et al. Short-term outcomes of aflibercept for neovascular agerelated macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol 2013; 156: 23-28. e2.
11. Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol 2013; 156: 29-35. e2.
12. Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 2013; 156: 15-22. e1.
13. Chang AA, Li H, Broadhead GK, Hong T, Schlub TE, Wijeyakumar W et al. Intravitreal aflibercept for treatmentresistant neovascular age-related macular degeneration. Ophthalmology 2014; 121: 188-192.
14. Heussen FM, Shao Q, Ouyang Y, Joussen AM, Müller B. Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2014; 252: 909-915.
15. Messenger WB, Campbell JP, Faridi A, Shippey L, Bailey ST, Lauer AK et al. Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration. Br J Ophthalmol 2014; 98: 1205-1207.
16. Grewal DS, Gill MK, Sarezky D, Lyon AT, Mirza RG. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Eye (Lond) 2014; 28: 895-899.
17. Gharbiya M, Iannetti L, Parisi F, De Vico U, Mungo ML, Marenco M. Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Biomed Res Int 2014; 2014: 273754.
18. Arcinue CA, Ma F, Barteselli G, Sharpsten L, Gomez ML, Freeman WR. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J Ophthalmol 2015; 159: 426-36. e2.
19. Singh RP, Srivastava S, Ehlers JP, Bedi R, Schachat AP, Kaiser PK. A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis. Br J Ophthalmol 2014; 98(Suppl 1): i22-i27.
20. Pinheiro-Costa J, Costa JM, Beato JN, Freitas-da-Costa P, Brandão E, Falcão MS et al. Switch to aflibercept in the treatment of neovascular AMD: one-year results in clinical practice. Ophthalmologica 2015; 233: 155-161.
21. Aiello L, Brucker A, Chang S, Cunningham Jr ET, D'Amico DJ, Flynn HW Jr et al. Evolving guidelines for intravitreous injections. Retina 2004; 24: S3-S19.
22. Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol 2012; 96: 1-2.
23. Ehlken C, Jungmann S, Böhringer D, Agostini HT, Junker B, Pielen A. Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye (Lond) 2014; 28: 538-545.
24. Wykoff CC, Brown DM, Maldonado ME, Croft DE. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol 2014; 98: 951-955.
25. He L, Silva RA, Moshfeghi DM, Blumenkranz MS, Leng T. Aflibercept for the treatment of retinal pigment epithelial detachments. Retina 2016; 36: 492-498.
26. Sarao V, Parravano M, Veritti D, Arias L, Varano M, Lanzetta P. Intravitreal Aflibercept for choroidal neovascularization due to age-related macular degeneration unresponsive to ranibizumab therapy. Retina 2016; 36: 770-777.